Assembly Biosciences doses first two participants in Phase 2 trial of hepatitis delta drug ABI-6250
ASMB•Assembly Biosciences dosed the first two participants in a Phase 2 trial of ABI-6250 for chronic hepatitis delta virus infection. The trial targets about 80 participants, with initial data expected in the fourth quarter of 2027; Gilead holds an exclusive licensing option for $90 million through Phase 2 completion and review of the option data package.
1. Phase 2 trial begins
Assembly Biosciences dosed the first two participants in a Phase 2 trial of oral ABI-6250 for chronic hepatitis delta virus infection. The trial targets approximately 80 participants and will test two once-daily doses for safety and antiviral activity.
2. Data and licensing option
Initial Phase 2 data are expected in the fourth quarter of 2027. Phase 1a results supported further development, and the drug’s mean half-life of approximately four days supports once-daily dosing. Gilead holds an exclusive licensing option for ABI-6250 for $90 million through Phase 2 completion and review of the option data package.
